ReviewBrain, behavior, & immunity - health2026
The dual role of arginine vasopressin in immune regulation: Balancing immunostimulation and immunosuppression.
Review in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Arginine vasopressin (AVP) is a pleiotropic neuroendocrine hormone with diverse physiological functions that have important implications for immune regulation. Although AVP has been reported to exert both immunostimulating and immunosuppressive effects, its actions on immune function are highly context-dependent and arise largely from its established roles in stress physiology, vascular regulation, osmoregulation, and thermoregulation. AVP influences immune activity indirectly through modulation of the hypothalamic-pituitary-adrenal (HPA) axis, blood flow, vascular and lymphatic permeability, fluid balance, and fever responses - all of which shape immune cell trafficking, activation, and inflammatory signaling. In addition, the expression of AVP and its receptors on immunocompetent cells - including T cells, dendritic cells, macrophages, neutrophils, and microglia - supports a role for direct, cell-specific AVP signaling, although the functional consequences of these interactions remain incompletely defined. AVP signaling affects both innate and adaptive immune responses by altering immune cell proliferation, migration, differentiation, and cytokine production in a manner that depends on receptor subtype, cellular content, and physiological state. These immunomodulatory properties are particularly relevant in conditions characterized by neuroendocrine dysregulation, including chronic stress, acquired brain injury, and autoimmune disease, where AVP contributes to cerebral edema, blood-brain barrier disruption, dysregulated HPA axis feedback, and secondary immune activation. This review synthesizes current evidence describing how AVP shapes immune function through integrated neuroendocrine, vascular, and cellular mechanisms, highlights key gaps in mechanistic understanding, and discusses the therapeutic potential - and limitations - of targeting AVP signaling in inflammatory and neuroimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.